Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AGA Amplatzer Pivotal Study Investigator Draws FDA Warning Letter

This article was originally published in The Gray Sheet

Executive Summary

A principal investigator in AGA Medical's Amplatzer septal occluder pivotal study, currently under PMA review, was cited in an FDA warning letter for failure to properly report issues of informed consent, patient follow-up and compassionate use of the device

You may also be interested in...

Sulzer Medica

Spine-Tech unit President Dennis Wallach also will lead the Cardiovascular Prostheses unit following the departure of its leader Terry Marlatt, announced Dec. 4. Wallach had replaced Paul Lunsford at Spine-Tech on Oct. 17 when Lunsford left to become president and CEO of Acorn Cardiovascular (1"The Gray Sheet" Oct. 29, 2001, p. 8). Merging the management of the two Sulzer units will help reduce costs, the firm says. Separately, John Calhoun Wells has been hired by Sulzer and plaintiffs as a mediator to help settle ongoing hip and knee recall cases. Wells was named by the Cleveland federal district court under a Nov. 29 agreement by the two sides in order to prevent the company from being forced into Chapter 11 by suits outside its $783 mil. proposed settlement (2"The Gray Sheet" Dec. 3, 2001, p. 20)...

Amplatzer Postmarket Study Should Address Age, Device Size Issues - Panel

FDA approval of AGA Medical's Amplatzer septal occluder should include a requirement for a five-year postmarket study of patients under 10 years of age who receive the device, the agency's Circulatory System Devices Panel recommended at its Sept. 10 meeting in Gaithersburg, Maryland.

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts